Review of the presentation by HJ Schmoll EORTC GI Group. [Preoperative chemoradiotherapy with capecitabine and oxaliplatin vs capecitabine alone in locally advanced rectal cancer: response to the local treatment… read more.
A review of the presentation by Rene Adam MD (pictured). There has been considerable progress in the overall survival of patients with colorectal cancer taking chemotherapy.
by Pam Harrison – MSI status has clear prognostic value in stage II CRC Julien Taieb, MD, PhD, University of Paris Descartes, Paris, France Microsatellite instability (MSI), a… read more.
We ask Professor Heinz-Josef Lenz, Professor of Medicine, Associate Director Clinical Research what he thinks is going to be the next big thing in colorectal cancer for the… read more.
EMA Highlights by Gary Finnegan – The EMA’s Committee for Medicinal Products for Human Use (CHMP) has a new member: Ivana Mikacic has been nominated by Croatia which… read more.
FDA Highlights by Bruce Sylvester – Researchers report from a phase I clinical trial report that diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy have been successfully reprogrammed… read more.
A new study links fetal exposure to a common chemical pollutant, bisphenol A (BPA), to defects of a testicular hormone in newborn boys with undescended testicles. The results… read more.
Matthias Holdhoff, MD, PHD, Assistant Professor of Oncology. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Dr Erin Dunbar, Assistant Professor and Co. Director, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Department of Neurosurgery, University of Florida.
Dr Brian Healey Bird FCPI. Consultant Medical Oncologist, Bon Secours Cork. Senior Clinical Lecturer, University College Cork.
Similar trends found in UK, Australia and US. Missed diagnoses―particularly of cancer, heart attack, and meningitis―and drug errors make up the bulk of malpractice claims brought against doctors… read more.
Poster 67 Elizabeth Goode elizabeth.goode@nnuh.nhs.uk. Chemotherapy is an independent risk factor for thromboembolism (TE), although current guidelines do not recommend routine use of anti-thrombin agents in this setting.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
